EUCTR2015-003101-42-CZ进行中（未招募）1 期
A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids - SINUS-24
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication / intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:
- •-An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).
- •-Ongoing symptoms (for at least 8 weeks prior to V1) of nasal congestion / blockage / obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at the time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).
- •-Signed written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 437
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 43
排除标准
- •-Patients <18 years of age.
- •-Patient who has previously been treated in dupilumab studies.
- •-Patient who has taken:
- •-Biologic therapy/systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.
- •-Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.
- •-Anti-immunoglobulin E (IgE) therapy (omalizumab) within 130 days prior to V1.
- •-Patients who are receiving leukotriene antagonists/modifiers at V1 unless they are on a continuous treatment for at least 30 days prior to V1.
- •-Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.
- •-Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months prior to V1.
- •-Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.
- •-Patients with conditions/concomitant diseases making them nonevaluable at V1 or for the primary efficacy endpoint such as:
- •-Antrochoanal polyps.
- •-Nasal septal deviation that would occlude at least one nostril.
- •-Acute sinusitis, nasal infection or upper respiratory infection.
- •-Ongoing rhinitis medicamentosa.
- •-Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis), Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary syndromes, concomitant cystic fibrosis.
- •-Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.
- •-Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc).
- •-Patients with forced expiratory volume in 1 second (FEV1) 50% or less (of predicted normal).
- •-Patients receiving concomitant treatment prohibited in the study.
- •-Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.
- •-History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.
- •-Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.
- •-Active chronic or acute infection requiring systemic treatment within 2 weeks before the baseline visit.
- •-Known or suspected history of immunosuppression.
- •-Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.
- •-Women unwilling to use adequate birth control, if of reproductive potential and sexually active.
研究者
相似试验
进行中（未招募）
1 期
A Controlled Clinical Study of Dupilumab in Patients with Nasal PolypsEUCTR2015-003101-42-HUSANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT240
进行中（未招募）
1 期
Controlled Clinical Study of Dupilumab in Patients with Nasal Polypsnasal polypsMedDRA version: 19.0 Level: PT Classification code 10028756 Term: Nasal polyps System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-003101-42-GBSANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT276
进行中（未招募）
1 期
Controlled Clinical Study of Dupilumab in Patients with Nasal Polypsnasal polypsMedDRA version: 19.0 Level: PT Classification code 10028756 Term: Nasal polyps System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-003101-42-FRSANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT276
进行中（未招募）
1 期
Controlled Clinical Study of Dupilumab in Patients with Nasal Polypsnasal polypsMedDRA version: 19.0Level: PTClassification code 10028756Term: Nasal polypsSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-003101-42-NLSANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT240
进行中（未招募）
1 期
Controlled Clinical Study of Dupilumab in Patients with Nasal Polypsnasal polypsMedDRA version: 20.0Level: PTClassification code 10028756Term: Nasal polypsSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-003101-42-BGSANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT276